Evidence map›Paper›PMID 42361282›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026

Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.

Makoto Tahara, Naomi Kiyota, Takeshi Kodaira, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Yuji Hirayama, Yusuke Onozawa, Naoki Nishio, Nobuhiro Hanai and 23 more

Abstract readClinical Trial, Phase IIClinical Trial, Phase IIIEquivalence Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Makoto TaharaNational Cancer Center Hospital East, Kashiwa, Japan.ORCID 0000-0001-9035-3106
Naomi KiyotaKobe University Hospital, Cancer Center, Kobe, Japan.ORCID 0000-0001-8021-6116
Takeshi KodairaAichi Cancer Center Hospital, Nagoya, Japan.ORCID 0000-0002-7075-8488
Hiroshi NishinoJichi Medical University Hospital, Shimotsuke, Japan.ORCID 0000-0001-6236-8167
Yukinori AsadaMiyagi Cancer Center, Natori, Japan.
Hiroki MitaniCancer Institute Hospital, Tokyo, Japan.
Yuji HirayamaHyogo Cancer Center, Akashi, Japan.
Yusuke OnozawaShizuoka Cancer Center, Shizuoka, Japan.
Naoki NishioNagoya University Hospital, Nagoya, Japan.ORCID 0000-0003-1495-0376
Nobuhiro HanaiAichi Cancer Center Hospital, Nagoya, Japan.ORCID 0000-0003-2524-8283
Akira OhkoshiTohoku University Hospital, Sendai, Japan.ORCID 0000-0003-0652-7041
Hiroki HaraSaitama Cancer Center, Ina, Japan.ORCID 0000-0003-3881-9815
Nobuya MondenNHO Shikoku Cancer Center, Matsuyama, Japan.
Masato NagaokaJikei University School of Medicine, Tokyo, Japan.ORCID 0000-0001-6350-5186
Shujiro MinamiNHO Tokyo Medical Center, Tokyo, Japan.ORCID 0000-0002-7992-4868
Kaoru TanakaKindai University Hospital, Sakai, Japan.ORCID 0000-0002-4927-1368
Takashi FujiiOsaka International Cancer Institute, Osaka, Japan.
Seiichi YoshimotoNational Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0001-9270-095X
Tsutomu UedaHiroshima University Hospital, Hiroshima, Japan.ORCID 0000-0001-9771-3880
Yo KishimotoKyoto University, Kyoto, Japan.ORCID 0000-0002-3583-0165
Akihiro HommaHokkaido University Hospital, Sapporo, Japan.ORCID 0000-0003-1488-0646
Nobuhiko OridateYokohama City University Hospital, Yokohama, Japan.ORCID 0000-0002-6968-3028
Kenji OkamiTokai University School of Medicine, Isehara, Japan.
Hirokazu UemuraNara Medical University, Kashihara, Japan.ORCID 0000-0001-7502-3619
Katsunori KatagiriIwate Medical University, Shiwa, Japan.ORCID 0000-0002-6436-2559
Tomoko YamazakiSaitama Medical University International Medical Center, Hidaka, Japan.ORCID 0000-0001-9654-5280
Takahiro AsakageInstitute of Science Tokyo Hospital, Tokyo, Japan.
Yuki SaitoThe University of Tokyo Hospital, Tokyo, Japan.
Shigeyuki MuronoFukushima Medical University Hospital, Fukushima, Japan.ORCID 0000-0002-0544-9590
Junki MizusawaJapan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0001-8123-5298
Kenichi NakamuraNational Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0003-3534-8296
Ryuichi HayashiNational Cancer Center Hospital East, Kashiwa, Japan.
Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The interim analysis of JCOG1008 demonstrated that chemoradiotherapy with cisplatin 40 mg/m

Indexed as

Antineoplastic AgentsChemoradiotherapyCisplatinHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckAdultAgedDrug Administration ScheduleFemaleFollow-Up StudiesHumansMaleMiddle AgedAntineoplastic AgentsCisplatin

Identifiers

PMID42361282
PMCPMC13581295

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.